Oncology Drug Reference Sheet: Elacestrant.

The article provides information on elacestrant, an estrogen receptor (ER) antagonist which was granted by the U.S. Food and Drug Administration an application priority review and fast-track designation, with regular approval in January 2023. Topics discussed include dosing and administration, adverse reactions, and nursing considerations.